FDA Approves Drug Combo for Gastric/GEJ Adenocarcinoma

Article

The FDA approved ramucirumab (Cyramza) in combination with paclitaxel for treating patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Single-agent ramucirumab was approved in April for gastric and gastroesophageal junction adenocarcinoma.

The US Food and Drug Administration (FDA) approved the monoclonal anti-VEGFR2 antibody ramucirumab (Cyramza) in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. This follows an approval in April of this year for these malignancies that were refractory to or progressive following first-line treatment with platinum-based or fluoropyrimidine chemotherapy.

The new approval, which came out of an orphan drug designation by the FDA, is based on a large study of 655 patients with previously-treated advanced or metastatic gastric or GEJ adenocarcinoma. Patients received either the combination of ramucirumab and paclitaxel (330 patients) or placebo with paclitaxel (335 patients). The median overall survival was 9.6 months with ramucirumab and 7.4 months with placebo, yielding a hazard ratio (HR) of 0.81 (95% CI, 0.68-0.96; P = .017).

Progression-free survival was also significantly improved with ramucirumab. The HR for progression-free survival was 0.64 (95% CI, 0.54-0.75; P < .001).

Among 656 patients who received at least one dose of the study drug, the most frequent adverse events were fatigue/asthenia, neutropenia, diarrhea, and epistaxis. The most common serious adverse events with ramucirumab were neutropenia (3.7% of patients) and febrile neutropenia (2.4% of patients).

These results were initially presented at the 2014 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in January. At the time, the lead author Hansjochen Wilke, MD, of the Kliniken Essen-Mitte in Germany said the 2-month improvement in overall survival was “an astonishingly good result in such a challenging patient population. The result was statistically significant and also clinically meaningful.”

Ramucirumab hasn’t been completely successful in treating these malignancies, however. The combination drug seems to make an important difference, as results presented at the 2014 ASCO Annual Meeting showed: adding ramucirumab to the FOLFOX regimen did not delay progression among patients with untreated advanced gastric or esophageal adenocarcinoma. The drug did provide a longer progression-free survival and improved disease control rate in certain patients, however.

Ramucirumab, an angiogenesis inhibitor, in combination with other agents such as docetaxel has also shown promise in other malignancies including nonsmall-cell lung cancer. It is currently under investigation in other cancers including advanced liver cancer and other solid tumors.

Related Videos
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content